BMY vs PLRZ: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

BMY is the larger of the two ($126.33B market cap): the incumbent the market prices for continued execution (9.23x forward earnings, beta 0.19). PLRZ is the smaller challenger ($26.84M): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

BMY vs PLRZ: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricBMYPLRZWhat it tells you
Market cap$126.33B$26.84MSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Beta0.19-1.12Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range71% of range53% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book5.400.96How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how BMY and PLRZ affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BMY and PLRZ share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BMY and PLRZ exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Bristol Myers Squibb (BMY) do?

Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. It makes money primarily by selling patented branded drugs, with a portfolio that has historically leaned on blockbuster franchises such as the blood thinner Eliquis (co-marketed with Pfizer), the cancer immunotherapy Opdivo, and the multiple myeloma drug Revlimid. The company is working through a major patent cliff as several legacy products lose exclusivity, and it is rebuilding growth through a newer portfolio that includes drugs like Reblozyl, Opdualag, Camzyos, Sotyktu, and the schizophrenia treatment Cobenfy (acquired through Karuna). Bristol Myers grows both organically through its research pipeline and through large acquisitions (Celgene, MyoKardia, Karuna, Mirati). It is headquartered in New York and operates worldwide.

Full BMY guide

What does Polyrizon (PLRZ) do?

Polyrizon Ltd. is a development-stage biotechnology company based in Israel that develops intranasal hydrogel products delivered as nasal sprays. Its proprietary Capture and Contain (C&C) technology is designed to form a thin hydrogel barrier in the nasal cavity, intended to act as a kind of biological shield against allergens and airborne viruses, while its Trap and Target (T&T) platform aims to improve nasal delivery and retention of drugs. The lead program is NASARIX (PL-14), an allergy blocker, alongside earlier-stage candidates such as a viral-blocker program. The company has no approved products and generates no product revenue.

Full PLRZ guide

BMY vs PLRZ: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • BMY drivers: New product portfolio ramp; Oncology and immunology depth.
  • PLRZ drivers: Differentiated non-invasive approach; Lead program moving toward the clinic.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. For PLRZ, polyrizon is a pre-revenue, development-stage micro-cap, so the risks are severe and concentrated.

BMY or PLRZ: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BMY if you believe its drivers more; PLRZ if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BMY and PLRZ guides.

BMY vs PLRZ: the full fundamentals

BMY. At about $60.80 on October 16, 2026, Bristol Myers trades near 9 times forward earnings, still low relative to large-cap pharma peers, which reflects market skepticism about replacing patent-cliff revenue even after a 40% one-year rally. The 4.2% dividend yield and strong cash flow are the bull-case anchors, while consensus for roughly flat 2027 EPS (about $6.62 versus $6.65 for 2026) captures the bear case. The 24 analysts in Yahoo's consensus carry a mean target near $66, and Q3 2026 results arrive on October 29.

PLRZ. For a pre-revenue biotech like Polyrizon there are no earnings or P/E to analyze; the market value of about $24 million reflects speculation on whether products such as NASARIX can eventually reach the market, and it sits below the company's book value (about 0.84x). The most important numbers are cash versus burn rate: about $16.1 million at June 30, 2026 plus the $4.0 million raised in September, against a trailing net loss of about $4.6 million. Runway looks adequate for now, but the shelf registration and small share count mean future financings could significantly dilute existing holders.

Headline figures (approximate, October 2026): BMY shows revenue (ttm) ~$49.2 billion (Q2 2026 up ~5.7% YoY), q2 2026 adjusted eps $2.04 vs $1.60 consensus, operating margin ~34%, net income (ttm) ~$9.3 billion; PLRZ shows product revenue None (development-stage), net loss (ttm) ~$4.6 million, operating loss (2025) ~$6.2 million, cash (june 30, 2026) ~$16.1 million, no debt (plus ~$4.0 million raised in September).

The bottom line: BMY vs PLRZ

BMY and PLRZ are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BMY and PLRZ exposure against your real portfolio. It is not an investment adviser.

Wondering how BMY or PLRZ fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Bristol Myers Squibb

Ask Walnut's AI anything about BMY and see how it fits what you own.

FAQ

What is the difference between BMY and PLRZ?

+

Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. Polyrizon Ltd. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is BMY or PLRZ the better stock?

+

Neither is universally better. BMY is the larger incumbent; PLRZ is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, BMY or PLRZ?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both BMY and PLRZ?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of BMY vs PLRZ?

+

BMY: The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. Revlimid has already declined under generic entry. The newer portfolio must scale fast enough to offset these losses, which is not guaranteed, and consensus already pencils in flat to lower revenue and EPS in 2027. Drug pricing pressure (including US Medicare negotiation under the Inflation Reduction Act, which named Eliquis), clinical trial failures, regulatory setbacks, and integration risk from large acquisitions all weigh on the outlook; the split admilparant readout in October 2026, which also came with protocol changes and a patient death the company said was likely unrelated, is a reminder of how quickly pipeline news can move the stock. Debt of about $45 billion against about $11 billion of cash, and litigation exposure, add further uncertainty. PLRZ: Polyrizon is a pre-revenue, development-stage micro-cap, so the risks are severe and concentrated. Its products are early-stage and could fail in clinical or regulatory testing, leaving little or no commercial value. As a single-platform company it has limited diversification, and it has no approved products, no revenue, and ongoing operating losses, meaning it depends on raising more capital; its $50 million shelf, prior placements and the $4.0 million offering of September 2026 point to dilution that can erode existing shareholders. It has already navigated a Nasdaq listing compliance process and a cancelled reverse split, both signs of the financial fragility common to companies this small. The shares are thinly traded and highly volatile, and an investment could result in substantial or total loss.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BMY or PLRZ; figures are approximate and dated (as of November 2026). Verify current data before investing.